Bringing Qaelon’s voice to LSI Europe 2025

Aligning your data strategy with corporate objectives from day one isn’t just a best practice—it’s essential. Investors want confidence that your organization can deliver clinical evidence that’s structured not only for regulatory compliance and marketing, but also for long-term monetization. Starting with that alignment creates a solid foundation for trust and credibility.

For early-stage medical device companies, a strategic partnership with data, clinical, and regulatory experts—whether internal or external—is absolutely critical. It allows you to:

• Focus on product development and the unique value of your device, while ensuring you've derisked the regulatory pathway.

• Launch with robust clinical data that validates your claims and economic value.

• Position your data as a tangible asset, opening doors to direct monetization.

• Build a resilient data architecture that endures well beyond initial approvals and supports scale.

By integrating these strategies early on, you not only reduce risk—you construct a narrative of assurance and foresight that resonates deeply with investors.

Qaelon CEO, Liam Burns will be speaking on a panel at LSI Europe exploring how medtech start-ups can collectively drive smarter, more impactful innovation in MedTech.

The panel includes some of the most respected voices in health care, including:

• Ryan Roberts — Chief Commercial Officer, Veranex

• C. David Adair, MD, MBA, FACOG, FASH, C-EFM — Co-Founder, Managing Partner, Solas BioVentures

• Nicolas Borenstein — Scientific Director, President of Preclinical Services, Veranex

• Carine Schorochoff — CEO, Cardiawave

• Jose Pablo Morales, MD — Former FDA

If you’re attending LSI Europe, join the conversation — we’d love to see you there.